Upregulated levels of mRNA for inflammasome components (NLRP1, NLRP3, PYCARD, caspase 1, 5 and 8) and downstream effectors (IL-1β, IL-18) in severe and mild AD cases. Increased mRNA and protein levels of caspase-1, NLRP3, GSDMD, and IL-1β in PBMCs of aMCI/AD patients, higher plasma and CSF IL-1β levels in aMCI and AD patients. This evidence concerns the gene IL18 and Alzheimer disease.